Select a therapy to learn how Right to Thrive is bringing the next generation of care to patients in the United States.
Our flagship therapy uses peptide-based personalized cancer vaccines designed to train the immune system to recognize and attack tumor-specific neoantigens. Developed in collaboration with our design and manufacturing partner, Glyphic Biotechnologies.
